GenEdit

📍 South San Francisco, United States🗓 Founded 2016👥 48 employees💰 Last funded Nov 2018
Biotechnology Research🌐 GenEdit.com
Website LinkedIn
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
South Korea
1
Investor activity2017–2018 · investors recorded per year
2017120182
Recent (last 2y)Earlier
Frequently asked questions
Who invested in GenEdit?
GenEdit has 3 investors on record on gritt.io, including 3 early-stage backers.
When did GenEdit last raise funding?
The most recent investment in GenEdit recorded on gritt.io was in November 2018.
When was GenEdit founded?
GenEdit was founded in 2016.
What industry is GenEdit in?
GenEdit operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GenEdit based?
GenEdit is headquartered in South San Francisco, United States.